These data demonstrate that targeting the FLT3-TAZ axis with either the combination of FLT3 inhibitor with TKI or single treatment with ponatinib alone can abolish drug resistance and render CML cells vulnerable to continued TKI treatment. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.